SARASOTA, Fla., Oct. 14, 2004 (PRIMEZONE) -- The following is an investment opinion issued by eLocity Inc.:
Galaxy Minerals (OTCBB:GAXY), Net2Phone, Inc. (Nasdaq:NTOP), INAMED Corp. (Nasdaq:IMDC) and Genzyme Corp. (Nasdaq:GENZ).
Mining stock investors may want to take a look at a little known company called Galaxy Minerals (OTCBB:GAXY). Galaxy announced after the closing bell Wednesday, "That it has taken a large step toward production at its Yellow Jacket Mine Property in Santa Cruz County, Arizona. As recently stated by the Company, Galaxy now intends to complete pre-production planning at the Yellow Jacket Project, with Phase III commencing immediately."
Operations Director Bruce Oettel stated, "Phase III Operations on the Yellow Jacket Mine looks to be exciting as the data gathered to date has been very encouraging. It is anticipated that the coarse gold found in recent assays may be in evidence throughout the workings. With this infusion of cash, we will get to the point of pre-production faster."
GAXY is currently trading at around .40 a share.
On the Nasdaq;
Net2Phone, Inc. (Nasdaq:NTOP)
Voice and enhanced telecommunication services provider Net2Phone, Inc. announced after the bell Wednesday results for the fourth quarter reporting a loss narrower than analysts' estimates and a rise in revenues over last year. The company recorded quarterly net loss of $6.3 million, or $0.08 per share, compared to a net loss of $10.8 million, or $0.18 per share, in the year-ago quarter.
Net2Phone's quarterly net loss was $3.2 million compared to a net loss of $2.9 million in the year-ago quarter before special and non-cash items. The company's revenues for the quarter rose to $21.1 million from $21.0 million over last year.
Shares of NTOP closed Wednesday's regular trading session up .06 at $3.61, and was trading higher at $3.69 in the after hours market.
INAMED Corp. (Nasdaq:IMDC) and Genzyme Corp. (Nasdaq:GENZ)
INAMED Corp. (Nasdaq:IMDC) and Genzyme Corp. (Nasdaq:GENZ) jointly announced after the bell Wednesday that the FDA has granted market approval for sales of Hylaform Plus, a large particle size hyaluronic acid-based skin filler used to correct moderate to severe facial wrinkles and folds.
The company said Hylaform Plus was developed and is manufactured by Genzyme Corporation and Inamed is Genzyme's exclusive worldwide marketing and distribution partner for Hylaform Plus. The new product gives physicians in the U.S. a new, effective non-surgical tool to treat the deepest wrinkles and provide optimal facial contouring.
Shares of IMDC closed Wednesday's regular session at $47.65, and GENZ ended the trading session at $51.07.
About eLocity Inc: eLocity owns and operates three financial websites for investors.
-PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.
-StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers". We rank stocks on volume, message board activity, sentiment and trend forecast.
-Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.
Sign up for FREE at any of the sites above.
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company". The company is to receive compensation for newsletter services for Galaxy Minerals, (public company). The compensation is forty thousand dollars from a non-affiliated third party Knights Bridge Capital Corp. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.
The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.
The company relies exclusively on information gathered on the public company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the public company in order to allow the investor to form his or her own opinion regarding the public company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.
Investing in the public company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.
The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.